Astellas Acquires Mitobridge Under Existing Collaboration

Astellas Acquires Mitobridge Under Existing Collaboration

Firm News

On November 30, 2017, Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function. Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition.

Rosemary Reilly leads the WilmerHale team representing Mitobridge in this transaction, which also includes Steve Barrett, Bill Caporizzo, Jeff Hermanson, Andrew Langworthy, Benjamin Kelsey and Nils Remole.

Astellas and Mitobridge's full press release can be found on www.mitobridge.com

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.